| Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators ES Moon, F Elvas, G Vliegen, S De Lombaerde, C Vangestel, ... EJNMMI Radiopharmacy and Chemistry 5, 19, 2020 | 73 | 2020 |
| 18F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy S De Bruycker, C Vangestel, T Van den Wyngaert, P Pauwels, L wyffels, ... Journal of Nuclear Medicine 60, 34-40, 2018 | 24 | 2018 |
| Baseline [18F]FMISO μPET as a predictive biomarker for response to HIF-1α inhibition combined with 5-FU chemotherapy in a human colorectal cancer xenograft model S De Bruycker, C Vangestel, T Van den Wyngaert, A Wouters, P Pauwels, ... Molecular imaging and biology 18 (4), 606-616, 2016 | 18 | 2016 |
| Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [18F]HX4 PET imaging study in colorectal cancer xenografts S De Bruycker, C Vangestel, S Staelens, L Wyffels, J Detrez, ... EJNMMI research 9, 1-10, 2019 | 14 | 2019 |
| How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research S De Bruycker, C Vangestel, S Staelens, T Van den Wyngaert, ... Contrast Media & Molecular Imaging 2018, 4608186, 2018 | 13 | 2018 |
| Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status J Van den Bossche, A Domen, M Peeters, C Deben, I De Pauw, J Jacobs, ... Cancers 11 (12), 1893, 2019 | 9 | 2019 |
| ATG4B inhibitor UAMC-2526 potentiates the chemotherapeutic effect of gemcitabine in a panc02 mouse model of pancreatic ductal adenocarcinoma FS Takhsha, C Vangestel, M Tanc, S De Bruycker, M Berg, I Pintelon, ... Frontiers in Oncology, 4509, 2021 | 7 | 2021 |
| Early Changes in [18F] FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts Y Dockx, C Vangestel, T Van den Wyngaert, M Huizing, S De Bruycker, ... Molecular imaging 2021, 1-14, 2021 | 4 | 2021 |
| 18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies Y Dockx, C Vangestel, S De Bruycker, T Van den Wyngaert, M Huizing, ... Cancer Biotherapy & Radiopharmaceuticals, 2022 | 2 | 2022 |
| Imaging biomarkers for the modulation of the hypoxic tumor microenvironment S De Bruycker University of Antwerp, 2019 | | 2019 |
| [18F]HX4 shows potential as a predictive biomarker for the radiosensitizing capacities of metformin in a NSCLC xenograft model SD Bruycker, C Vangestel, TV Wyngaert, S Deleye, D Vanderghinste, ... Cancer Research 77 (13_Supplement), 1875-1875, 2017 | | 2017 |
| [18F]-FDG-PET as an early response predictor in a HER-2 overexpressing, trastuzumab-resistant breast cancer model treated with targeted PI3K/Akt/mTOR drugs. Y Dockx, C Vangestel, S De Bruycker, M Huizing, P Pauwels, ... JOURNAL OF NUCLEAR MEDICINE 56 (2), 22-22, 2015 | | 2015 |
| [18F]FMISO µPET as a potential predictive biomarker of 5-FU therapy resistance in a xenograft mouse model for colorectal cancer S De Bruycker, C Vangestel, T Verbrugghen, P Pauwels, ... JOURNAL OF NUCLEAR MEDICINE 56 (2), 6-7, 2015 | | 2015 |
Christel VangestelPostdoctoral fellowship, University Hospital Antwerp, University of AntwerpGeverifieerd e-mailadres voor uantwerpen.be
